Partnership Event | 2020 Venture Café BioConnect
On June 25th , 2020 Venture Café BioConnect Virtual Conference embraced the best innovative minds to discuss and share on Life Sciences trends and opportunities. CUBIC, partnering with Venture Café, invited Xiyong Fu, president of US R&D of Luye Pharma, Shawn Xu, Managing Partner of Simcere Innovation, Yang Xie, VP Biology of Jacobio, and Xiaojun Liu, Life Sciences advisor of CUBIC from our network to contribute China related insights.
Diversity in Biotech
The Diversity in Biotech session features Dan Gebremedhin of Flare Capital partners and Dr. Xiyong Fu of Luye US R&D in a discussion of personal experiences and strategies for building, running, growing, and funding successful tech ventures.
Dr. Xi-Yong Fu is the President of Luye US R&D. As a part of Luye’s global R&D network, US R&D consists of Boston R&D Center which is responsible for developing innovative biologics assets and novel drug delivery technologies and the Clinical Development organization based in Princeton New Jersey which filed two NDAs and are managing a number of late phase clinical studies in US. Under the leadership of Dr. Fu, Luye’s US R&D operation has emerged as a preeminent R&D centers in US established by a China biotech company. Prior to joining Luye, Dr. Fu was the President of Cureport Inc. Before that, Dr. Fu worded at Merck & Co., for 15 years with a wide range of responsibilities covering R&D, business development, finance and operational management.
Industry Insights: Solutions for Covid-19
What has been changed and what needs to be changed during the Covid-19 pandemic? The 2 top tier Chinese pharmaceutical companies, Simcere and Jacobio, will share their unique experience and insights on the innovation landscape and actions post Covid-19. Their topics are “China’s pharmaceutical industry in the era of COVID-19” and “the true story of how Jacobio kept doing R&D during Covid-19”.
As a founding member, Dr. Xu successful established Simcere Innovation, Inc. in Boston in 2019, dedicating to research and development of advanced cell and gene therapies for patients. He is responsible for overseeing the overall operations of the company in Boston, developing and implementing Simcere Innovation’s strategies, including innovation models, internal R&D strategy and external innovation. In addition, he works closely with Simcere Pharmaceutic Group’s management team in China and BD team in US for the corporate’s R&D strategies and oversea external opportunities, including in-licensing and investment. Dr. Xu has almost 20 years’ experience in the top pharmaceutical industries and academic institute, including Johnson & Johnson, Hengrui Medicine and the University of Rochester. He led and participated in 30+ R&D projects of discoveries and early development in cell therapies, biologics and small molecule drugs, including several compounds are at IND and clinical development stages.
Dr. Yang Xie is the VP Biology in Jacobio Pharmaceuticals. Jacobio is a China-headquartered clinical stage biotech dedicated in oncology drug R&D. Yang is responsible for establishing and managing Jacobio’s US laboratory in greater Boston, with a focus on translational medicine, new project search, evaluation & initiation, and supporting clinical operations in the US. Before Jacobio, Yang has 10+ years of biopharma experience working in Forma Therapeutics and Novartis, leading programs from target ID to pre-IND. As an expert in cancer biology and target therapy development, Yang published extensively in leading journals of Nature, Cell, PNAS, Genes & Dev, etc, with 2500+ citations. Yang is also an active practitioner in technology evaluation & commercialization and led cross-border pipeline evaluations resulting in $100M+ investment. Yang obtained his Ph.D. from Yale University, and BA from Peking University.
Special Office Hour
Xiaojun is a life science veteran with over 20 years of Research, Commercial and Entrepreneurial experience in both US and Chinese markets. He started his career as a medicinal chemist at Pfizer Groton site. He then switched to commercial side of life science industry, leading multiple new product launches in global and Chinese market for Eli Lilly and Genzyme (acquired by Sanofi). His last corporate position was global marketing director for Charles River Lab，managing marketing activities for its Discovery Services and Toxicology Services (> $700M revenue). As an serial entrepreneur, Xiaojun has co-founded several healthcare startups in US and China. He led the exit of the virtual drug discovery company, Northlake International, by successfully selling its key asset to large pharma. Xiaojun holds a BS degree from Peking University, MS in Chemistry from University of Pittsburgh, and MBA from Kellogg School of Management.